DHA 2020.1 sbir phase i medical r & d purchase order, proposal number H201-002-0028, titled "prophylactics for ionizing radiation-induced hematopoietic subsyndrome of ARS"
Ended Purchase Order Awarded Last action
- Contract number
- W81XWH20P0130
- Awardee
-
Zymeron Corporation UEI GAMMMRQ6QMN1
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $249,992
Award facts
- Opportunity
-
- HQ003420R1DSB Solicitation number
- Contract value 100% obligated
- $249,991.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AN91 R&D- Medical: Other (Basic Research)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 57 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $249,992 |
About this award
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Zymeron Corporation, a Minority Owned Small Business, under the Small Business Innovation Research (SBIR) program. The $249,991.85 Phase I award supports research and development of "Prophylactics for Ionizing Radiation-Induced Hematopoietic Subsyndrome of Acute Radiation Syndrome (ARS)". The contract has a completion date of July 23, 2021. Zymeron is a research-based biotechnology company that discovers, develops, and commercializes innovative technologies focused on areas like radiation exposure treatments, infectious disease diagnostics and therapies, and drug delivery systems. This SBIR Phase I award aligns with the DHA's biomedical advancement and public health mission.
Quick answers
Who was awarded contract W81XWH20P0130?
W81XWH20P0130 was awarded to Zymeron Corporation by Medical Command (Department of the Army) on August 28, 2020.
How much is contract W81XWH20P0130 worth?
The government has obligated $249,992 on W81XWH20P0130.
Which agency awarded contract W81XWH20P0130?
Medical Command (Department of the Army) awarded W81XWH20P0130, with funding from Defense Health Agency (Department of Defense).
Was contract W81XWH20P0130 competed?
The extent of competition for W81XWH20P0130 was full and open competition after exclusion of sources. The government received 57 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award